Align Technology, Inc. is a global medical device company engaged in the design, manufacture, and marketing of digital orthodontic and restorative dentistry solutions. The company operates through two segments: Clear Aligner and Imaging Systems and CAD/CAM Services. Its primary product is the Invisalign System of clear aligners for treating malocclusions, accompanied by Vivera retainers for retention. The company also provides iTero intraoral scanners for digital dental imaging and exocad CAD/CAM software for dental laboratories and practitioners. These products are integrated into the Align Digital Platform, which supports end-to-end workflows including treatment planning, diagnosis, and monitoring. Align serves orthodontists, general dental practitioners, dental laboratories, and dental support organizations worldwide. The company was founded in 1997 and introduced the Invisalign System in 1999.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage aligntech.com
Sector Healthcare IR page investor.aligntech.com
Tags
orthodontics, clear aligners, intraoral scanners, cad/cam software, digital dentistry, restorative dentistry, dental imaging, treatment planning software, Invisalign, Vivera, iTero, exocad, Align Digital Platform, ClinCheck Pro, Invisalign Teen, Invisalign Express, iTero Lumina, iTero Lumina Pro, Align X-ray Insights, Invisalign SmileView, My Invisalign, Invisalign Practice App, iTero Element 5D, iTero NIRI, iTero TimeLapse, iTero-exocad Connector, Align Oral Health Suite, Invisalign Outcome Simulator Pro, Invisalign Professional Whitening System, Invisalign Palatal Expander System, SmartTrack, SmartForce, SmartStage, Invisalign Progress Assessment, Invisalign Virtual Care AI, Invisalign Smile Architect, Invisalign Doctor Locator, Invisalign Virtual Appointment
Press page aligntech.com/newsroom

Metrics

Valuation  
Market cap $ 10.275B
Market cap (USD) $ 10.275B
P/E 21.19
PEG 4.92
P/BV 2.39
P/S 2.47
P/OCF 13.70
P/FCF 17.05
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.4%
ROI 13.5%
ROIC 12.6%
Profit margin 10.2%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 4.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 46
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Revenue 4.035B 3.999B 3.862B 3.735B 3.953B 2.472B 2.407B 1.966B 1.473B 1.08B 845.486M 761.653M 660.206M 560.041M 479.741M 387.126M 312.333M 303.976M 284.332M 206.354M 207.125M 172.83M 122.725M 75.395M 46.384M — —
Net profit 410.351M 421.362M 445.053M 361.573M 772.02M 1.776B 442.776M 400.235M 231.418M 189.682M 144.02M 145.832M 64.295M 58.691M 66.716M 74.253M -31.269M 79.987M 35.724M -34.963M 1.413M 8.768M -20.122M -68.121M -97.474M -88.748M -15.415M
Free cash flow 490.778M 622.651M 608.06M 276.832M 771.446M 507.258M 597.563M 331.369M 242.844M 177.078M 184.546M 202.807M 166.564M 95.445M 100.065M 111.498M 66.973M 25.412M 45.348M -24.058M 2.287M 15.501M 4.537M -48.511M -97.03M -72.371M -14.096M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999
Share price 156.15 208.51 274 210.9 657.18 534.38 279.04 209.43 222.19 96.13 65.85 55.91 57.14 27.75 23.86 19.52 17.81 7 27.81 12.99 — — — — — 468.78 —
Price performance 12m -0.25 -0.24 0.3 -0.68 0.23 0.92 0.33 -0.06 1.31 0.46 0.18 -0.02 1.06 0.16 0.22 0.1 1.54 -0.75 1.14 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 247M 323M 439M 550M 658M 897M 860M 903M 996M 1.1B
↳ YoY growth +56.0% +30.5% +36.0% +25.3% +19.5% +36.4% -4.2% +5.1% +10.2% +10.7%
↳ 5y CAGR +22.0% +26.7% +31.1% +33.5% +32.9% +29.4% +21.6% +15.5% +12.6% +10.9%
Lease liabilities (USD) — — 0.00 59.2M 86.2M 125M 127M 127M 119M 114M
Cash and deposits (USD) 389M 450M 637M 550M 961M 1.1B 942M 937M 1.04B 1.09B
Intangible assets (USD) 21M 24.5M 17.9M 11.8M 130M 110M 95.7M 82.1M 103M 93.9M
Right-of-use assets (USD) — — 0.00 56.2M 82.6M 121M 119M 118M 113M 108M
Cash flow detail
Operating cash flow (USD) 248M 439M 555M 747M 662M 1.17B 569M 786M 738M 593M
Purchases of property, plant and equipment (USD) -70.6M -196M -223M -150M -155M -401M -292M -178M -116M -102M
Change in receivables (cash effect) (USD) -94.4M -91M -109M -121M -140M -262M 21.5M -105M -153M -140M
Change in inventories (cash effect) (USD) -7.66M -5.48M -24.1M -58.3M -29.1M -112M -130M 30.2M 25.1M 808,000
Change in payables (cash effect) (USD) -3.4M 8.18M 25M 22.1M 52.2M 19.7M -36.5M -7.7M -843,000 5.33M
Share buybacks (cash effect) (USD) -96.2M -104M -300M -400M 0.00 -375M -435M -592M -353M -466M
Income taxes paid (cash effect) (USD) -47.3M -51.2M -115M -71.7M -76.3M -203M -232M -295M -177M -135M
Share-based compensation (USD) 54.1M 58.9M 70.8M 88.2M 98.4M 114M 133M 154M 174M 186M
Operating cash flow before change in receivables (USD) 342M 530M 664M 868M 802M 1.43B 547M 890M 892M 733M
Free cash flow (OCF - PPE - intangibles) (USD) 177M 243M 331M 598M 507M 771M 277M 608M 623M 491M
Income detail
Research and development expense (USD) 75.7M 97.6M 129M 157M 175M 250M 305M 347M 364M 370M
↳ 5y CAGR +15.3% +17.9% +23.9% +24.4% +23.4% +27.0% +25.6% +21.9% +18.3% +16.1%
Total comprehensive income (USD) 190M 233M 397M 445M 1.82B 733M 347M 477M 406M 480M
Comprehensive income to owners (USD) 190M 233M 397M 445M 1.82B 733M 347M 477M 406M 480M
Provision for credit losses (USD) — — 870,000 5.85M 12.1M 2.81M — — — —
Credit cost ratio (credit losses / average receivables) (%) — — 0.2% 1.2% 2.0% 0.4% — — — —
Reported Feb 28, 2017 Feb 28, 2018 Feb 26, 2021 Feb 26, 2021 Feb 26, 2021 Feb 25, 2022 Feb 27, 2023 Feb 28, 2024 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Align Technology Zeno Group Bull 1 Bear 0 Management

Madelyn Valente Sarah Karlson

(909) 833-5839 (828) 551-4201

[email protected] [email protected]

PAUL J. CLANCY AND IAN BELL TO JOIN ALIGN TECHNOLOGY BOARD OF DIRECTORS

Paul J. Clancy, Ian Bell

TEMPE, Ariz. & SAN JOSE, Calif., November 18, 2026 — Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that its Board of Directors has appointed Paul J. Clancy, a biopharmaceutical executive and former Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc. and Biogen Inc., as a director effective immediately and Ian Bell, Senior Vice President and Chief Operating Officer of Alcon Inc., as a director effective December 10, 2026.

“We are pleased to welcome Paul Clancy to our Board and look forward to the addition of Ian Bell in December,” said Kevin Conroy, Chairman of the Board of Align Technology.

TEMPE, Ariz.--(BUSINESS WIRE)--Nov. 6, 2026-- Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it has entered into a new accelerated stock repurchase agreement (“ASR”) with Goldman Sachs & Co. LLC (“Goldman Sachs”), to repurchase $270 million of Align’s common stock under Align’s $1.0 billion stock repurchase program that was approved by Align’s Board of Directors in April 2025.

“This $270 million accelerated stock repurchase fulfills the share repurchase commitment we announced in July and is expected to bring our total 2026 share repurchases to approximately $500 million,” said John Morici, Align CFO and executive vice president, global finance. “This transaction reflects the confidence of our Board and management in Align’s long-term value. Our strong balance sheet and consistent cash generation profile provide us with the flexibility to return capital to stockholders while continuing to invest in the growth, innovation and productivity initiatives that support our long-term strategy.”

Under the terms of the ASR, Align will make a prepayment of $270 million to Goldman Sachs. The final number of shares to be repurchased will be based generally on the volume-weighted average price of Align common stock during the term of the ASR, less an agreed upon discount. The ASR transaction is expected to be completed on or about by December 29, 2026, although completion may occur earlier in certain circumstances. The ASR will be funded with Align’s cash on hand.

Following the $270 million ASR, Align expects approximately $330 million to remain available for future repurchases under the $1.0 billion stock repurchase program. As of September 30, 2026, Align had approximately $1.145 billion in cash and cash equivalents.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for approximately 307 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 24.2 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

Forward-Looking Statements

This news release contains forward-looking statements including statements regarding Align’s expectations regarding the amount of its share repurchases during 2026, the expected completion date of the ASR transaction, the number of shares of common stock that will be repurchased under the ASR, Align's expectation that it will finance the ASR transaction with cash on hand, Align’s capital allocation priorities, ability to generate cash and strength of Align’s balance sheet, and ability to return capital to stockholders while continuing to invest in its business, and its expectations regarding long-term growth and performance, as well as other statements regarding the ASR. Forward-looking statements contained in this news release relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement.

The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission ("SEC") on February 27, 2026, and our latest Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which was filed with the SEC on November 4, 2026. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261106269526/en/

Align Technology Madelyn Valente (909) 833-5839 [email protected]

Zeno Group Sarah Karlson (828) 551-4201 [email protected]

Source: Align Technology, Inc.

ALGN - (NASDAQ)

$166.00

+6.63

Nov 6, 2026 - 4:00 PM EST

Minimum 15 minutes delayed. Source: LSEG

Align recognized for executive leadership, investor relations and investor engagement in the Health Care Technology & Distribution sector

The 2026 awards mark Align’s fourth recognition in five years in the Extel All-America Executive Team rankings

TEMPE, Ariz. & SAN JOSE, Calif.--(BUSINESS WIRE)--Nov. 6, 2026-- Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced recognition in the 2026 All-America Executive Team rankings published by Extel Insights (formerly Institutional Investor Research), which evaluates the quality of investor relations programs, leadership, and governance as voted on by the buy- and sell-side analyst community. In the Health Care Technology & Distribution sector, Align earned first- and second-place rankings across three Large-Cap award categories – Best CEO, Best IR Program, and Best Investor Day – in both the Combined and Buy-side results.The 2026 awards mark Align’s fourth recognition in five years in the Extel All-America Executive Team rankings, reflecting the company’s longstanding commitment to transparent disclosure, meaningful investor engagement, and ongoing dialogue with shareholders and analysts.

2026 Extel All-America Executive Team Award Categories and Named Winners:

  • Best CEO: Joseph Hogan, President and Chief Executive Officer, ranked #2 in both the Combined, Large-Cap and Buy-side, Large-Cap results in the Health Care Technology & Distribution sector.

  • Best IR Program: Align’s Investor Relations Program ranked #2 in the Combined, Large-Cap results and #1 in the Buy-side, Large-Cap results in the Health Care Technology & Distribution sector.

  • Best Investor Day: Align’s Investor Day ranked #1 in both the Combined, Large-Cap and Buy-side, Large-Cap results in the Health Care Technology & Distribution sector.

Commenting on Align’s recognition in Extel’s All-America Executive Team rankings, Shirley Stacy, Align Technology vice president, finance, corporate communications and IRO said, “We’re grateful for this recognition from the investment community and proud of the work our teams do every day to provide clear, consistent and meaningful investor communications. That work is truly a team effort, bringing together our communications team and colleagues across legal, finance, clinical, and marketing whose expertise and partnership are essential to our investor relations efforts. Our focus is on helping investors fully understand our strategy, performance, long-term opportunities, and the potential of our business through transparent disclosure, thoughtful engagement, and ongoing dialogue. That commitment is especially important during dynamic and challenging market periods, when clear communication and accessibility matter most. We remain focused on continuing to earn the trust and confidence of our investors.”

In 2025, Align earned the Most Honored Company distinction, with its Board of Directors and Investor Relations Program each ranked first in the Large-Cap category and among the top 10 in the Health Care Technology & Distribution sector. In 2023, Align ranked third for Best IR Team and placed fourth on the Most Honored Company list, with its investor relations program highly rated for credibility, responsiveness, and market knowledge. In 2022, Align’s executive team and IR program received top-tier recognition, including first- and third-place rankings for CEO, CFO, and IR professionals, and second place for the overall IR program. These achievements were especially notable during the pandemic era, underscoring Align’s resilience and dedication to transparent communications.

Survey Methodology:

The All-America Executive Team rankings are based on comprehensive feedback from buy-side analysts, money managers, and sell-side researchers at securities firms and financial institutions, evaluating companies on leadership quality, investor relations programs, and engagement strategies. Extel asks voters to name the best chief executive officers, chief financial officers, and investor relations professionals at the companies in their coverage universes.

About Extel

For over 50 years, Extel (formerly Institutional Investor Research) has offered highly respected proprietary benchmark research and rankings, providing independent feedback on the sell-side and corporate performance; Extel aims to be the first-choice independent validation source of qualitative market intelligence for all three sides of the investment community and has a global presence spanning Europe, Emerging EMEA, Asia Pacific, North America and Latin America.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 307 thousand doctor customers and is key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 29 years, Align has helped doctors treat approximately 24.2 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align Digital Platform™, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

Prompts

Align Technology, Inc. (ticker ALGN), listed in United States.

ETFs Holding Align Technology, Inc.

ETF Weight in ETF Shares Market value As of
CAMX 3.63% 14,624 $ 2.474M Jul 31, 2026
KMID 3.44% 9,273 $ 1.569M Jul 31, 2026
LGHT 2.72% 399 $ 67.295K Jun 30, 2026
CGMM 1.62% 353,892 $ 58.739M Nov 16, 2026
DAK 1.58% 4,067 $ 660K Nov 18, 2026
RNIN 1.32% 16,898 $ 2.76M Nov 18, 2026
MKTN 1.21% 7,659 $ 1.292M Jun 30, 2026
BAFE 1.08% 108,583 $ 18.314M Jun 30, 2026
LSEQ 0.90% 889 $ 149.636K Nov 13, 2026
MMID 0.84% 1,896 $ 302.962K Aug 31, 2026
DSTL 0.78% 97,589 $ 16.459M Jun 30, 2026
FLCV 0.56% 4,868 $ 777.858K Aug 31, 2026
AFMC 0.48% 7,667 $ 1.273M Nov 16, 2026
JDOC 0.45% 271 $ 44.298K Nov 17, 2026
BTAL short -0.39% -6,578 $ -1.109M Jun 30, 2026
ITAN 0.36% 2,683 $ 438.563K Nov 17, 2026
DFAT 0.34% 643,734 $ 107.484M Nov 12, 2026
LSVD 0.34% 12,970 $ 2.194M Jul 31, 2026
GVLU 0.27% 4,261 $ 707.241K Nov 17, 2026
REMC 0.27% 54 $ 9,107.64 Jun 30, 2026
FLCG 0.24% 9,445 $ 1.509M Aug 31, 2026
FLCC 0.24% 2,013 $ 321.657K Aug 31, 2026
CGNG 0.24% 43,168 $ 7.165M Nov 16, 2026
DFAS 0.17% 349,343 $ 58.33M Nov 12, 2026
VFMF 0.15% 9,171 $ 1.465M Aug 31, 2026
AVMC 0.13% 4,176 $ 693.132K Nov 16, 2026
VFQY 0.13% 4,009 $ 640.598K Aug 31, 2026
SFGV 0.12% 8,295 $ 1.36M Nov 18, 2026
IALT 0.08% 39,088 $ 6.488M Nov 16, 2026
VFVA 0.07% 4,336 $ 692.849K Aug 31, 2026
CAPE 0.05% 722 $ 121.773K Jun 30, 2026
DFSU 0.04% 6,332 $ 1.057M Nov 12, 2026
DFAC 0.04% 229,615 $ 38.339M Nov 12, 2026
DXUV 0.04% 15,683 $ 2.619M Nov 12, 2026
DFUV 0.03% 30,068 $ 5.02M Nov 12, 2026
AVSU 0.03% 837 $ 138.925K Nov 16, 2026
AVLC 0.03% 2,889 $ 479.516K Nov 16, 2026
AVUQ 0.03% 720 $ 119.506K Nov 16, 2026
NBCR 0.03% 1,515 $ 242.082K Aug 31, 2026
DFAU 0.02% 16,616 $ 2.774M Nov 12, 2026
AVUS 0.02% 20,815 $ 3.455M Nov 16, 2026
DFUS 0.02% 23,275 $ 3.886M Nov 12, 2026
VSLU 0.02% 570 $ 96.136K Jun 30, 2026
DCOR 0.02% 42,436 $ 7.086M Nov 12, 2026
HCMT 0.01% 464 $ 78.49K Jul 31, 2026
MSLC 0.01% 2,734 $ 436.866K Aug 31, 2026
CSHP 0.01% 160 $ 26.557K Nov 16, 2026
GSPY 0.01% 252 $ 41.827K Nov 17, 2026
EBI 0.00% 73 $ 11.665K Aug 31, 2026
CORO 0.00% 42 $ 6,916.79 Nov 16, 2026
INRO 0.00% 13 $ 2,157.74 Nov 16, 2026
NTRL 0.00% 1,147 $ 0.00 Nov 16, 2026